证券代码：300143 证券简称：盈康生命 投资者关系活动记录表 编号：2025-07 投资者关 系活动类 别 ☑ 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 其他 （电话会议） 参与单位 名称及人 员姓名 南方基金 冯啸 秦乾一 张德曦 陈哲、东证资管 邹秉昂、华创自营 胡建东、易米基金 刘家曦、中泰证券 祝嘉琦 孙宇瑶 余燕伶、平 安证券 裴晓鹏、光大证券 吴佳青、中信证券 沈睦钧 王凯 时间 2025 年 9 月 11 日 地点 山东省青岛市崂山区海尔路 1 号盈康一生大厦 18 楼盈康生命科 技股份有限公司会议室 上市公司 接待人员 姓名 董事会秘书 刘泽霖 投资者关系总监 董丁梦 投资者关 系活动主 要内容介 绍 1、公司在 AI 医疗方面有比较长时间和广泛的布局，请具体介 绍下，以及从经营数据上看有哪些提升效果？ 回答：公司AI应用经历了1.0 阶段（统一整合旗下医院四大核 心系统，实现一体化整合，解决信息孤岛等问题）、2.0 阶段（建 设互联网医院平台，构建"线上+ 线下"一体化服务链，建设大数 据湖，搭建医院管理自日清平台）和AI 应用3.0 阶 ...

（编辑 王雪儿） 证券日报网讯 盈康生命8月26日发布公告，在公司回答调研者提问时表示，公司目前重要子公司主要为 圣诺医疗和优尼器械，圣诺医疗2025年上半年实现收入9723.16万元，同比提升11.21%，实现净利润 1670.68万元，同比提升28.70%。其主要产品在激烈的市场竞争中稳住市场份额，上半年公司输注泵国 内市占率超10%，排名提升至第3位；乳腺钼靶设备国内市占率约10%，排名第3位；高压输注设备及耗 材出货量持续引领。优尼器械上半年实现收入5076.65万元，同比提升12.59%，实现净利润1558.47万 元，同比提升37.75%。圣诺和优尼的渠道协同下，公司进一步突破三甲医院高端市场720多家，三甲医 院覆盖率已超40%。 ...

Financial Performance - The company achieved revenue of 843 million CNY in the first half of 2025, a year-on-year increase of 2.40% [3] - Net profit attributable to shareholders reached 61.83 million CNY, up 12.82% year-on-year [3] - Medical services segment revenue was 653 million CNY, growing 2.28% year-on-year [3] - Medical device segment revenue was 190 million CNY, with a year-on-year increase of 2.80% [3] Oncology Services - Revenue from oncology services reached 215 million CNY, a significant increase of 25.14% [3] - The number of level IV surgeries increased by 6.62% [3] - The outpatient volume at Friendship Hospital reached 24,200 visits, up 21.59% year-on-year [3] - The proportion of level IV surgeries at Friendship Hospital increased by 8 percentage points [3] Medical Device Market - The company’s infusion pump market share exceeded 10%, ranking third in the domestic market [16] - The mammography device market share is approximately 10%, also ranking third [17] - Overseas revenue for medical devices grew by 35% year-on-year [18] AI Integration - AI applications have improved clinical capabilities, reducing complication rates by 10% and average hospital stays by 1-2 days [15] - The efficiency of image diagnosis increased by 66%, and patient follow-up efficiency improved by 300% [15] - Patient Net Promoter Score (NPS) reached 92.5%, surpassing the industry average of 90% [15] Hospital Operations - Sichuan Friendship Hospital generated revenue of 291 million CNY, maintaining stability amid competition [6] - Suzhou Guangci Hospital achieved revenue of 269 million CNY, with a year-on-year growth of 1.69% [7] - The company’s managed hospitals, including Yuncheng Hospital, have seen significant operational improvements, with surgical volumes increasing by 18% [12] Strategic Developments - The acquisition of Changsha Kexin Oncology Hospital enhances the company’s oncology ecosystem and regional presence [10] - The company is focusing on differentiated services and expanding its service ecosystem through partnerships and AI integration [9]

中证报中证网讯(王珞)8月24日晚间，盈康生命（300143）发布半年度报告，数据显示，公司上半年实 现营业收入8.43亿元，同比增长2.4%；归属于上市公司股东的净利润6182.72万元，同比增长12.8%；扣 非归母净利润6058.99万元，同比增长19.2%，实现营收与净利润双增长。毛利率同比提升0.5个百分 点，费用率同比下降2个百分点，经营提质增效明显，公司实现持续高质量发展。 诊疗能力升级，驱动肿瘤规模及行业影响力提升。报告显示，公司肿瘤收入2.15亿元，同比增长 25.14%，肿瘤诊疗人次快速增长、肿瘤四级手术量显著增加。报告期内，友谊医院先后获评国家标准 化癌症筛查AAA级管理中心试点单位、CSCO"省市级肿瘤患者营养指导中心优秀单位"，区域口碑与专 业影响力持续强化，肿瘤诊疗能力和资质持续提升。 区域布局拓展至华中，外延式发展战略持续落地。盈康生命上半年收购长沙珂信肿瘤医院并完成交割， 该医院作为三级肿瘤专科医院，以肿瘤微创介入治疗技术为优势特色，头颈部肿瘤治疗能力实现区域引 领，长沙珂信的加入进一步丰富公司肿瘤预诊治康生态，为上市公司发展再添动能。 AI赋能提质增效 当前，盈康生命已实现" ...

Core Insights - The company reported a slight increase in revenue and a significant rise in net profit for the first half of 2025, attributed to both external acquisitions and internal growth driven by AI technology [1][2]. Financial Performance - The company achieved a revenue of 843 million yuan, a year-on-year increase of 2.4% [1]. - The net profit attributable to shareholders was 61.83 million yuan, reflecting a year-on-year growth of 12.8% [1]. Business Segments - The medical services segment generated 653 million yuan in revenue, with the oncology business being a key growth driver, contributing 215 million yuan, a 25.14% increase year-on-year [2]. - The company completed the acquisition of a 51% stake in Changsha Kexin Tumor Hospital for 357 million yuan, enhancing its presence in the central China region [2]. Operational Efficiency - The overall expense ratio decreased by 2 percentage points, while the average service volume per employee increased by 10% [3]. - The company reported an average revenue per employee of 710,000 yuan, up 8.9%, and an average profit per employee of 52,600 yuan, up 20.2% [3]. Market Expansion - The overseas market revenue grew by 35% year-on-year, while the domestic market share also showed steady improvement [3]. - The company achieved significant milestones in product registration and certification, including the EU MDR certification for its third-generation digital mammography machine [3]. Strategic Focus - The company aims to diversify its product offerings across tumor prevention, diagnosis, treatment, and health management to reduce reliance on overseas markets [5].

Core Viewpoint - 盈康生命 reported a solid performance in the first half of the year, achieving revenue growth and net profit increase, indicating a trend of high-quality development in the company. Financial Performance - The company achieved operating revenue of 843 million yuan, a year-on-year increase of 2.4% [1] - Net profit attributable to shareholders reached 61.83 million yuan, up 12.8% year-on-year [1] - Deducting non-recurring gains and losses, the net profit was 60.59 million yuan, reflecting a year-on-year growth of 19.2% [1] - Gross margin improved by 0.5 percentage points, while expense ratio decreased by 2 percentage points, showcasing operational efficiency [1] Medical Services Development - The core business in medical services generated revenue of 653 million yuan, a year-on-year increase of 2.28% [2] - Revenue from oncology services reached 215 million yuan, growing by 25.14% year-on-year, with significant increases in patient visits and advanced surgical procedures [2] - The company has established a comprehensive service system covering early screening, diagnosis, mid-to-late stage treatment, and rehabilitation management [2] Strategic Expansion - The company expanded its regional presence by acquiring Changsha Kexin Tumor Hospital, enhancing its capabilities in minimally invasive tumor treatment [2] - The acquisition is expected to enrich the company's oncology pre-diagnosis and treatment ecosystem, providing additional growth momentum [2] Innovative Service Offerings - The company is focused on integrating medicine with new technologies and experiences to meet diverse health needs [3] - New services include weight loss, precision anti-aging, and international medical services, alongside the introduction of over 100 new clinical technologies [3] - The company has pioneered brain-machine interface applications in healthcare, achieving notable surgical outcomes in Parkinson's treatment [3] AI Integration and Efficiency - The company has implemented a "medical + AI" strategy, leading to significant improvements in service capacity and operational efficiency [4] - Key metrics include a 10% increase in per capita service volume and a 2 percentage point reduction in overall expense ratio [4] - AI technologies have reduced surgical complications by 10% and improved various operational efficiencies, including a 66% increase in imaging diagnosis efficiency [4] Market Growth in Medical Devices - The company achieved a 35% year-on-year growth in overseas medical device revenue, driven by strategic market expansion [5] - In the domestic market, the company has upgraded its products and channels, achieving over 40% coverage in top-tier hospitals [5] - The company’s infusion pumps and mammography equipment have gained significant market share, ranking third in their respective categories [5] Global Market Strategy - The company employs a "one country, one policy" strategy for overseas market expansion, enhancing user experience and product application [6] - New partnerships with nine overseas distributors have been established, expanding coverage across multiple global regions [6]